🚀
Enjoy a 7-Day Free Trial Thru Nov 20, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Strategies Created by Users
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Canadian Insider
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
Instant Alerts
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruAI
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
All Topics
General Discussions
Investment Ideas
Strategies
Article Comments
Books
Feedback
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Drug Manufacturers
AbbVie Inc (BUE:ABBV)
News
AbbVie Inc - Cedear
0
BUE
:ABBV (USA) Â
Cedear
ARS 20300.00
(-12.31%)
Nov 11
On watch
P/E:
60.57
P/B:
51.09
Market Cap:
ARS 308.31T
($ 309.01B)
Enterprise V:
ARS 372.12T
($ 372.97B)
Volume:
10.05K
Avg Vol (2M):
811.00
Warning! GuruFocus detected 3 Severe warning signs with ABBV.
Try a 7-Day Free Trial
to check it out.
Trade In:
Volume:
10.05K
Market Cap ARS:
308.31T
Market Cap $:
309.01B
PE Ratio:
60.57
Avg Vol (2M):
811.00
Enterprise Value ARS:
372.12T
Enterprise Value $:
372.97B
PB Ratio:
51.09
Alerts
Website
Sources
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
Forecast
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
AbbVie Inc (BUE:ABBV) Stock News, Headlines & Updates
AbbVie Inc Stock News from GuruFocus
Total 45
1
2
Nov 12, 2024
Beyond Market Price: Uncovering AbbVie Inc's Intrinsic Value
GuruFocus News
•
5:00am
Nov 11, 2024
AbbVie (ABBV) Suffers After Schizophrenia Drug Trial Disappointment
GuruFocus News
•
2:25pm
AbbVie Inc (ABBV) Trading Down 12.67% on Nov 11
GuruFocus News
•
10:02am
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
PRNewswire
•
8:00am
Nov 07, 2024
Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
PRNewswire
•
8:00am
Nov 05, 2024
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
GuruFocus News
•
11:06pm
Oct 31, 2024
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
PRNewswire
•
8:00am
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
Marketwired
•
8:00am
AbbVie Inc (ABBV) Q3 2024 Earnings Call Highlights: Strong Growth in Ex-Humira Platform and Dividend Increase
GuruFocus News
•
1:09am
Q3 2024 AbbVie Inc Earnings Call Transcript
GuruFocus News
•
11:16pm
Oct 30, 2024
AbbVie Inc (ABBV) Stock Price Up 5.02% on Oct 30
GuruFocus News
•
11:02am
AbbVie Inc (ABBV) Q3 2024 Earnings: Revenue Beats at $14.46B, GAAP EPS Misses at $0.88
GuruFocus News
•
7:11am
AbbVie Reports Third-Quarter 2024 Financial Results
PRNewswire
•
7:00am
Oct 29, 2024
AbbVie to Acquire Aliada Therapeutics for $1.4 Billion, Expanding Alzheimer's Pipeline
Faizan Farooque
•
1:18pm
SkinSpirit joins Allergan Aesthetics in Supporting Girls Inc. and Empowering the New Generation of Women in STEM
PRNewswire
•
8:00am
Navigating Market Uncertainty: Intrinsic Value of AbbVie Inc
GuruFocus News
•
6:00am
Oct 28, 2024
AbbVie strengthens CNS research with $1.4B buyout of Aliada Therapeutics
Muslim Farooque
•
11:36am
AbbVie's Bold $1.4 Billion Bet: The Alzheimer's Breakthrough Investors Have Been Waiting For
Khac Phu Nguyen
•
11:10am
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
PRNewswire
•
8:00am
Oct 24, 2024
AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions
PRNewswire
•
11:00am
Oct 21, 2024
AbbVie's Botox Cosmetic Expands Use Beyond Facial Wrinkles
GuruFocus News
•
2:11am
Oct 19, 2024
BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)
PRNewswire
•
7:00pm
Oct 18, 2024
FDA Approves AbbVie's VYALEV as First 24-Hour Levodopa Infusion for Advanced Parkinson's
Faizan Farooque
•
12:34pm
Oct 17, 2024
U.S. FDA Approves VYALEVâ„¢ (foscarbidopa and foslevodopa) for Adults Living with Advanced Parkinson's Disease
PRNewswire
•
8:00am
Oct 16, 2024
Allergan Aesthetics to Present New Data at 2024 American Society for Dermatologic Surgery (ASDS) to Showcase Depth Across Facial Aesthetics and Insight into Patient Perception
PRNewswire
•
8:00am
Oct 15, 2024
Beyond Market Price: Uncovering AbbVie Inc's Intrinsic Value
GuruFocus News
•
6:00am
Oct 10, 2024
AbbVie Shares Rebound After Six-day Slump Despite Ongoing Challenges
Muslim Farooque
•
7:11am
Oct 04, 2024
Allergan Aesthetics and Girls Inc. Celebrate Six Years and Challenge You to Take the Pledge to Support Mentorship in STEM
PRNewswire
•
9:00am
Oct 02, 2024
Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
PRNewswire
•
8:00am
Oct 01, 2024
AbbVie to Host Third-Quarter 2024 Earnings Conference Call
PRNewswire
•
8:00am
The Art of Valuation: Discovering AbbVie Inc's Intrinsic Value
GuruFocus Research
•
6:00am
Sep 27, 2024
AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
PRNewswire
•
12:00pm
Sep 26, 2024
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
PRNewswire
•
8:00am
Sep 25, 2024
New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
PRNewswire
•
7:00am
Sep 24, 2024
Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns
PRNewswire
•
8:00am
Sep 20, 2024
AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer
PRNewswire
•
7:00am
Sep 17, 2024
Navigating Market Uncertainty: Intrinsic Value of AbbVie Inc
GuruFocus Research
•
6:00am
Sep 11, 2024
Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China
PRNewswire
•
8:00am
Sep 09, 2024
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
PRNewswire
•
9:00am
Sep 06, 2024
AbbVie Declares Quarterly Dividend
PRNewswire
•
10:00am
Total 45
1
2
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news